CVE:ADK DIAGNOS (ADK) Stock Price, News & Analysis C$0.30 +0.01 (+1.67%) (As of 12/4/2024 05:23 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesInsider Trades About DIAGNOS Stock (CVE:ADK) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get DIAGNOS alerts:Sign Up Key Stats Today's RangeC$0.30▼C$0.3150-Day RangeC$0.26▼C$0.3852-Week RangeC$0.23▼C$0.57Volume220,550 shsAverage Volume92,964 shsMarket CapitalizationC$24.84 millionP/E RatioN/ADividend Yield0.29%Price TargetC$1.50Consensus RatingStrong Buy Company OverviewDIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. DIAGNOS Inc. was founded in 1998 and is headquartered in Brossard, Canada.Read More… What will be the biggest trades of 2025? (Ad)From Government Secrets to Triple-Digit Wins The 3 Profit Structures You Need to Know - REGISTER HERE.Click HERE to save your spot in this training event and let Steve show you. Receive ADK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DIAGNOS and its competitors with MarketBeat's FREE daily newsletter. Email Address ADK Stock News HeadlinesDIAGNOS Second Quarter 2025 Earnings: Revenues DisappointNovember 23, 2024 | finance.yahoo.comDIAGNOS Announces Cross-listing of its Common Shares on the Frankfurt Stock ExchangeNovember 12, 2024 | finance.yahoo.comWhat will be the biggest trades of 2025?From Government Secrets to Triple-Digit Wins The 3 Profit Structures You Need to Know - REGISTER HERE.December 5, 2024 | 10 Minute Trades (Ad)DIAGNOS Inc.: DIAGNOS Announces Voting Results of Meeting of ShareholdersOctober 1, 2024 | finanznachrichten.deADK:CA DIAGNOS Inc.September 21, 2024 | seekingalpha.comDIAGNOS First Quarter 2025 Earnings: EPS Beats Expectations, Revenues LagAugust 23, 2024 | finance.yahoo.comGot $1,000? 2 Stocks to Buy Now While They’re on SaleFebruary 23, 2024 | ca.finance.yahoo.comDIAGNOS recognized as a Top TSX Venture Exchange CompanyFebruary 21, 2024 | finance.yahoo.comSee More Headlines ADK Stock Analysis - Frequently Asked Questions How have ADK shares performed this year? DIAGNOS's stock was trading at C$0.41 at the start of the year. Since then, ADK stock has decreased by 24.7% and is now trading at C$0.31. View the best growth stocks for 2024 here. How do I buy shares of DIAGNOS? Shares of ADK stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. What other stocks do shareholders of DIAGNOS own? Based on aggregate information from My MarketBeat watchlists, some other companies that DIAGNOS investors own include DIAGNOS (DGNOF), Facedrive (FDVRF), New Found Gold (NFGC), Ackroo (AKR), BeWhere (BEW), BlueRush (BTV) and Grande West Transportation Group (BUS). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Health Information Services Sub-IndustryN/A Current SymbolCVE:ADK CUSIPN/A CIKN/A Webwww.diagnos.ca Phone+1-450-6788882FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price TargetC$1.50 High Stock Price TargetC$1.50 Low Stock Price TargetC$1.50 Potential Upside/Downside+391.8%Consensus RatingStrong Buy Rating Score (0-4)3.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)C($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeC$-3,090,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-134.33% Debt Debt-to-Equity Ratio245.28 Current Ratio0.39 Quick Ratio0.68 Sales & Book Value Annual SalesC$577,486.00 Price / Sales43.01 Cash FlowC$0.01 per share Price / Cash Flow60.00 Book ValueC($0.03) per share Price / Book-10.17Miscellaneous Outstanding Shares81,440,000Free FloatN/AMarket CapC$24.84 million OptionableNot Optionable Beta-0.44 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (CVE:ADK) was last updated on 12/5/2024 by MarketBeat.com Staff From Our PartnersLock in this share price before 12/5When the team that built Zillow into a $16B real estate leader launches a new company, it’s worth paying atten...Pacaso | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredStrange: Why is Amazon suddenly yielding 39.70%?Something big is happening with Amazon stock… While most investors collect ZERO dividends from Amazon… A...Investors Alley | SponsoredWhat will be the biggest trades of 2025?From Government Secrets to Triple-Digit Wins The 3 Profit Structures You Need to Know - REGISTER HERE.10 Minute Trades | SponsoredFed Declares War on AmericansFed Declares War on Americans Protect your wealth in the coming months… True Gold Republic | SponsoredThe 2024 TECH RESETAre we on the edge of the biggest ‘TECH RESET’ in decades?InvestorPlace | SponsoredMeet the NYSE traded company behind a potentially blockbuster antiviral drugThis public company’s one lead drug alone, NV-387, potentially addresses a $2.5 to $4.3 billion market Imag...Smallcaps Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DIAGNOS Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DIAGNOS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.